3417 related articles for article (PubMed ID: 26850970)
1. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
4. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
5. Rapidly changing landscape of PET/CT imaging in prostate cancer.
Morigi JJ; Fanti S; Murphy D; Hofman MS
Curr Opin Urol; 2016 Sep; 26(5):493-500. PubMed ID: 27467137
[TBL] [Abstract][Full Text] [Related]
6. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
7. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
De Visschere PJL; Standaert C; Fütterer JJ; Villeirs GM; Panebianco V; Walz J; Maurer T; Hadaschik BA; Lecouvet FE; Giannarini G; Fanti S
Eur Urol Oncol; 2019 Feb; 2(1):47-76. PubMed ID: 30929846
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
11. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Lin CY; Lee MT; Lin CL; Kao CH
Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
[TBL] [Abstract][Full Text] [Related]
13. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
14. The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.
Sathianathen NJ; Butaney M; Konety BR
World J Urol; 2019 Jul; 37(7):1239-1249. PubMed ID: 30003375
[TBL] [Abstract][Full Text] [Related]
15. The use of PET/CT in prostate cancer.
Li R; Ravizzini GC; Gorin MA; Maurer T; Eiber M; Cooperberg MR; Alemozzaffar M; Tollefson MK; Delacroix SE; Chapin BF
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):4-21. PubMed ID: 29230009
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer PET tracers: essentials for the urologist.
Fraum TJ; Ludwig DR; Kim EH; Schroeder P; Hope TA; Ippolito JE
Can J Urol; 2018 Aug; 25(4):9371-9383. PubMed ID: 30125515
[TBL] [Abstract][Full Text] [Related]
17. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.
Sonni I; Baratto L; Iagaru A
PET Clin; 2017 Apr; 12(2):159-171. PubMed ID: 28267450
[TBL] [Abstract][Full Text] [Related]
18. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Koschel S; Murphy DG; Hofman MS; Wong LM
Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
[TBL] [Abstract][Full Text] [Related]
19. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
